Skip to main content
PMC home page
BMC Cancer logoLink to BMC Cancer
. 2014 Jul 26;14:538. doi: 10.1186/1471-2407-14-538

Expression of miR-34c induces G2/M cell cycle arrest in breast cancer cells

Chandrani Achari 1,✉, Sofia Winslow 1,✉, Yvonne Ceder 1, Christer Larsson 1,✉
PMCID: PMC4125691  PMID: 25064703

Abstract

Background

MicroRNA-34 is a family of three miRNAs that have been reported to function as tumor suppressor miRNAs and show decreased expression in various cancers. Here, we examine functions of miR-34c in basal-like breast cancer cells.

Methods

Data from The Cancer Genome Atlas (TCGA) were used for evaluation of expression in primary breast cancers. Cellular processes affected by miR-34c were investigated by thymidine incorporation, Annexin V-assays and cell cycle analysis using breast cancer cell lines. Effects on potential targets were analyzed with qPCR and Western blot.

Results

TCGA data revealed that miR-34c was expressed at lower levels in basal-like breast cancer tumors and low expression was associated with poor prognosis. Ectopic expression of miR-34c in basal-like breast cancer cell lines resulted in suppressed proliferation and increased cell death. Additionally, miR-34c influenced the cell cycle mainly by inducing an arrest in the G2/M phase. We found that expression levels of the known cell cycle-regulating miR-34 targets CCND1, CDK4 and CDK6, were downregulated upon miR-34c expression in breast cancer cell lines. In addition, the levels of CDC23, an important mediator in mitotic progression, were suppressed following miR-34c expression, and siRNAs targeting CDC23 mimicked the effect of miR-34c on G2/M arrest. However, protein levels of PRKCA, a predicted miR-34c target and a known regulator of breast cancer cell proliferation were not influenced by miR-34c.

Conclusions

Together, our results support the role of miR-34c as a tumor suppressor miRNA also in breast cancer.

Electronic supplementary material

The online version of this article (doi:10.1186/1471-2407-14-538) contains supplementary material, which is available to authorized users.

Keywords: Breast cancer cells, miRNA-34c, CDC23, PKCα, Cell cycle arrest

Background

MicroRNAs (miRNAs) are small (~22 nt) non-coding RNAs of importance for protein level regulation. They act by interacting with the 3’UTR of the target mRNA which may cause mRNA degradation or translational inhibition [1, 2]. Several miRNAs have been associated with processes involved in cancer progression, e.g. proliferation, differentiation, apoptosis and tumorigenesis [3] and miRNAs have been classified as both oncogenic and tumor suppressive [4].

The miR-34 family consists of three homologous miRNAs located at chromosome 1 (miR-34a) and chromosome 11 (miR-34b/c) at positions frequently deleted in solid tumors, e.g. neuroblastoma, breast, prostate and lung cancer [5–9]. Several reports have also pointed out a decreased expression of miR-34 in numerous malignancies, such as miR-34c in prostate cancer [10], miR-34a and -34c in colon [11] and lung cancer [12], miR-34a in neuroblastoma [13], and miR-34a and -34b in breast cancer [14, 15]. Many studies report tumor suppressor-like effects of miR-34, for instance in ovarian cancer [16], prostate cancer [10], and neuroblastoma cells [5], putatively by regulating the expression of common miR-34 targets such as CCND1 [17], CCNE2 [18], CDK4 [18, 19], CDK6 [17, 20], MET [18, 19, 21, 22] and E2F3 [5, 20].

A recent study with prostate cancer PC3 cells revealed that miR-34c expression also resulted in downregulation of protein kinase Cα (PKCα) mRNA [21]. In addition, five target prediction tools (MiRanda [23], DIANAmT [24], miRWALK [25], PICTAR5 [26] and Targetscan [27] predict PRKCA as a putative miR-34c target. From a breast cancer perspective this could be of relevance since PKCα expression has been reported to be important for optimal breast cancer cell proliferation [28, 29], support a cancer stem cell-like breast cancer cell population [30] and to predict poorer survival [28].

Taken together, these facts led us to investigate putative suppressive effects of miR-34c on growth properties of breast cancer cells. We found that miR-34c overexpression both blocks the proliferation of cultured basal-like breast cancer cells and induces cell death, although this was not mediated by PKCα downregulation.

Methods

Cell Culture

All cell lines were obtained from American Type Culture Collection. MDA-MB-231, MDA-MB-468, BT-549 and T47D breast cancer cells were maintained in RPMI 1640 medium (HyClone, Thermo Scientific) supplemented with 10% fetal bovine serum (Saveen & Werner AB), 1 mM sodium pyruvate (HyClone, Thermo Scientific) and 100 IU/ml penicillin-streptomycin solution (HyClone, Thermo Scientific). The media for BT-549 cells were additionally supplemented with 0.01 mg/ml insulin (Novo Nordisk A/S) and for T47D with 1% glucose.

Transfections

For miRNA transfections, cells were seeded at 50–60% confluency and grown in complete medium without antibiotics for 24 h. Cells were thereafter transfected for 5 hours with miRIDIAN microRNA Mimic (80 nM probe, Dharmacon, Lafayette, CO, USA) using 2 μl/ml Lipofectamine 2000 (Invitrogen) in Opti-MEM I (Invitrogen) followed by 96 hour incubation in complete medium, roughly according to the manufacturer’s recommendations. Control experiments were performed in parallel, transfecting cells with miRIDIAN microRNA Mimic Negative Control (Dharmacon). Transfection with 40 nM siRNA (Stealth RNAi, Invitrogen) was performed for 72 hours (sequences are listed in Table 1) according to the manufacturer’s protocol.

Table 1.

siRNA nucleotides

siRNA oligonucleotide Sequence
Control 48% GC UUACGGAUCGACUUAAGCCGUUGCA
CDC23 I GCUGCCCAGUGUUACAUCAAAUAUA
CDC23 II UAUAUUUGAUGUAACACUGGGCAGC
CDC23 III CCAAGCUCGAGAACUUGAUGGAUUU
Open in a new tab

Thymidine incorporation

Cells were seeded in triplicates at a density of 5 × 104 cells per well in 12-well plates and transiently transfected for 5 hours. Cells were incubated with 1 μCi/ml [3H]-thymidine for 6 hours before harvesting the cells with 10 mM EDTA. The amount of radioactivity was measured with a Tri-carb 2810TR liquid scintillation analyzer (Perkin Elmer).

Cell cycle analysis

MDA-MB-231, MDA-MB-468 and BT-549 cells were seeded at a density of 150,000 cells per 35-mm cell culture dish and transiently transfected for 5 hours. Subsequently, cells were trypsinized and fixed in 70% ethanol for 20 minutes at −20°C, washed in PBS, and incubated with a solution containing 3.5 μM Tris- HCl pH 7.6, 10 mM NaCl, 50 μg/ml propidium iodide (PI), 20 μg/ml RNase, and 0.1% igepal CA-630 for 20 minutes on ice to label DNA. 10,000 events were acquired on the FL-2 channel for the PI signal. Sample acquisition and analyses were performed with CellQuest or FACSuite software (BD Biosciences).

Annexin V analysis

MDA-MB-231 and BT-549 cells were seeded at a density of 150,000 cells per 35-mm cell culture dish, and MDA-MB-468 cells were seeded at 200,000 cells per 35-mm cell culture dish and transfected for 5 hours. After 96 hour incubation in complete medium, floating cells, pooled with trypsinized adherent cells, were stained with Annexin V-allophycocyanin (APC; BD Pharmingen) according to the supplier’s protocol, and the amount of bound Annexin V-APC was quantified with a FACSCalibur cytometer (BD Biosciences). 10,000 events were acquired on the FL-4 channel for the Annexin V-APC signal.

Real-time qPCR

Total RNA was extracted from MDA-MB-231, MDA-MB-468 and BT549 cells with the RNeasy kit (Qiagen), and potential DNA contamination was eliminated with the RQ1 RNAse-Free DNase (Promega). Two micrograms of total RNA was used for cDNA synthesis with MultiScribe Reverse Transcriptase (Applied Biosystems). The cDNA was thereafter amplified by qPCR for evaluation of relative mRNA expression levels in an Applied Biosystems 7300 real-time quantitative PCR system using the SYBR Green PCR Master Mix (Applied Biosystems). The mRNA expression data were normalized to three reference genes (SDHA, UBC and YWHAZ). For relative quantification of gene expression, the comparative Ct method was applied. The sequences of primers are listed in Table 2.

Table 2.

qPCR primers

Primers for qPCR Sequence 5’ to 3a
SDHA forward TGGGAACAAGAGGGCATCTG
SDHA reverse CCACCACTGCATCAAATTCATG
YWHAZ forward ACTTTTGGTACATTGTGGCTTCAA
YWHAZ reverse CCGCCAGGACAAACCAGTAT
UBC forward ATTTGGGTCGCGGTTCTTG
UBC reverse TGCCTTGACATTCTCGATGGT
PRKCA forward AAACATCTCCACCCAAGACG
PRKCA reverse AATCCCTCCCTGCTCACTCT
CCND1 forward CCCTCGGTGTCCTACTTCAA
CCND1 reverse CTCCTCGCACTTCTGTTCCT
CDCK4 forward TGTGGAGTGTTGGCTGTATCTT
CDCK4 reverse GGTCGGCTTCAGAGTTTCC
CDCK6 forward TGGTGCCTCCTCTTGTCTG
CDCK6 reverse CTGCCTGTTCCCACTACTCC
CDC23 forward CGGAGTTGGCTTTCTCTCTC
CDC23 reverse CCTGGGCATCTTCCTCTGTA
Open in a new tab

For analysis of miR-34b/c expression levels, total RNA was extracted from MDA-MB-231, MDA-MB-468 and T47D cells with Trizol according to manufacturer’s instructions (Invitrogen). Small RNAs were reversely transcribed with miRNA specific primers, quantified by the TaqMan MicroRNA assays (Applied Biosystems) and normalized to two reference genes (RNU44 and U47).

Western blot analysis

Cells were lysed in radioimmune precipitation assay buffer (10 Mm Tris–HCl (pH 7.2), 160 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and 1 mM EGTA) containing 40 μl/ml Complete protease inhibitor (Roche Applied Science) and incubated on ice for 30 min. Lysates were cleared by centrifugation at 14,000 × g for 10 min at 4°C, diluted in sample buffer containing β-mercaptoethanol, and boiled for 5 min. Protein concentration was determined by Bradford assay, equal amount of proteins were electrophoretically separated on either 10% or 12% NuPAGE Novex BisTris gels (Invitrogen) and transferred to polyvinylidene difluoride membranes (Millipore). Membranes were blocked with phosphate-buffered saline containing 5% nonfat milk and probed with antibodies to Cyclin D1 and PKCα (1:500; Santa Cruz Biotechnology), CDK4 (1:1000; Millipore), CDK6 (1:1000; Cell Signaling Technology), CDC23 (1:1000, Abcam) and actin (1:1000; MP Biomedicals). Proteins were visualized with horseradish peroxidase-labeled secondary antibody (Amersham Biosciences) using the SuperSignal system (Pierce) as substrate. Chemiluminescence was detected using a CCD camera (Fujifilm).

Data analysis

HiSeq miRNA expression data of 658 breast tumors and 86 normal breast tissue samples and mRNA data from corresponding samples were downloaded from the TCGA database (http://cancergenome.nih.gov/). The data used were downloaded in December 2013. The tumors were clustered based on mRNA expression data using the hclust function in R. Survival analyses were performed on the 310 breast tumors that had follow up data using the Survival package. The TCGA “New tumor event” variable (recurrence) defined as new tumor event after initial treatment was used as end point for survival analyses. Pairwise comparisons were evaluated with a t-test.

Results

Expression of miR-34 in breast cancer

To assess putative roles of miR-34 family members in breast cancer, miRNA HiSeq expression data from 658 tumors and 86 normal breast tissue samples from the TCGA (The Cancer Genome Atlas) database were used. There was a clear correlation between miR-34b and miR-34c levels, whereas neither of them displayed a strong correlation with miR-34a (Figure 1A-C). This likely reflects the fact that miR-34b and 34c are located at the same locus on chromosome 11q23 whereas miR-34a is located at 1p36. The TCGA tumors were clustered using mRNA data, which separated the tumors in two major groups which correspond to basal-like and non-basal-like tumors. For miR-34c, lower levels were seen in basal-like tumors compared both to non-basal-like tumors and to normal breast tissue, whereas no substantial difference was observed for miR-34a or miR-34b (Figure 1D-F).The miR-34 expression data from the 310 tumors with follow-up information were split into two groups based on the median of the expression and survival curves with new tumor event as end point were generated (Figure 1G-I). No obvious difference between tumors expressing high or low levels of miR-34a could be seen. However, for both miR-34b and miR-34c, there was a difference in new tumor events between the low- and high-expressing groups, with more new tumor events in the group with miR-34 expression below median.

Figure 1.

Figure 1

Open in a new tab

Analysis of miR-34 family members using breast cancer TCGA data. Pair-wise scatter-plots of the expression of miR-34a, −34b and -34c in 658 miRNA HiSeq breast tumor samples from TCGA (A-C). Box plots demonstrate log2 expression levels of miR-34a (D), miR-34b (E) and miR-34c (F) in basal-like tumors, non-basal-like tumors and non-malignant breast tissue. Indicated p-values were calculated with a t-test comparing the group with the basal-like tumor samples. Kaplan-Meier analysis curves were constructed using the 310 TCGA tumors that had miRNA HiSeq data and follow-up data (G-I). The expression data were divided based on median expression and new tumor event was used as end point.

The levels of miR-34b and miR-34c were analyzed in two ER-negative (MDA-MB-231 and MDA-MB-468) and one ER-positive (T47D) cell line. In the ER-negative MDA-MB-468 cell line the levels were barely detected whereas the magnitude of expression was similar in the other cell lines (Additional file 1).

Expression of miR-34c decreases cell proliferation in breast cancer cells

Only miR-34c was expressed at lower levels in basal-like tumors. To investigate putative effects of miR-34c on breast cancer cell growth, three basal-like breast cancer cell lines, MDA-MB-231, MDA-MB-468 and BT-549, were transfected with miR-34c mimic or a scramble control oligonucleotide followed by [3H]-thymidine incorporation. In concordance with effects in other cell types [10, 16, 18], a suppressed proliferation with around 50% was observed following miR-34c transfection in all evaluated cell lines (Figure 2A-C).

Figure 2.

Figure 2

Open in a new tab

Effect of miR-34c on proliferation of breast cancer cells. MDA-MB-231 (A), MDA-MB-468 (B) and BT-549 (C) breast cancer cells were transiently transfected with either a miR-34c mimic or negative control for 96 h and then subjected to thymidine incubation for 6 hours. Data (mean ± SEM from three separate experiments) are expressed as [3H]-thymidine incorporation related to control cells. Asterisks indicate statistically significant differences (* p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t-test) compared to control cells.

Effect of miR-34c on cell cycle distribution

The suppressed [3H]-thymidine incorporation suggests that miR-34c may influence the cell cycle. The cell cycle distribution was thus analyzed by FACS following nuclear staining with propidium iodide (Additional file 2). Ectopic expression of miR-34c induced an accumulation of cells in the G2/M phase compared to control in MDA-MB-231 (Figure 3A) and MDA-MB-468 (Figure 3B) cells. A similar tendency was observed for BT-549 cells (Figure 3C). In all three cell lines a significant increase in sub-G1 phase was detected along with a reduction of cells in G1 phase (Figure 3A-C), but the G1-arrest that has been reported for other cell types [18, 31] was not detected in the breast cancer cells.

Figure 3.

Figure 3

Open in a new tab

Effect of miR-34c on cell cycle distribution of breast cancer cells. Following transfection of MDA-MB-231 (A), MDA-MB-468 (B) and BT-549 (C) breast cancer cells with miR-34c mimic or negative control for 96 h, nuclei were stained with propidium iodide solution and analyzed for DNA content by flow cytometry. Data (mean ± SEM, n = 5) represent percentage cells in different phases of the cell cycle with miR-34c related to scramble treatment. Asterisks indicate statistically significant differences (* p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t-test) compared to control cells.

Expression of miR-34c leads to increased cell death in breast cancer cells

The increase in nuclei in sub-G1 phase induced by miR-34c suggests that high expression of miR-34c can lead to induction of cell death. This was therefore analyzed with an Annexin V assay. In all cell lines, the number of Annexin V-positive cells was roughly doubled, indicating an increased cell death, following miR-34c overexpression (Figure 4 A-C).

Figure 4.

Figure 4

Open in a new tab

Effect of miR-34c on apoptosis of breast cancer cells. MDA-MB-231 (A), MDA-MB-468 (B) and BT-549 (C) breast cancer cells were transiently transfected with either miR-34c mimic or negative control for 96 h. After 96 h, cells were subjected to Annexin V-APC staining and flow cytometry analysis. Data (mean ± SEM, n = 2-3) represent percent AnnexinV-positive cells with miR-34c related to scramble treatment. Asterisks indicate statistically significant differences (* p < 0.05, Student’s t-test) compared to control cells.

Evaluation of miR-34c targets in breast cancer

As mentioned in the introduction, PRKCA is a predicted miR-34c target. Since PKCα is important for optimal breast cancer cell proliferation [28–30] we analyzed the effects of miR-34c on PKCα expression. We could not detect any effects on the protein levels (Figure 5A) despite the observation that PRKCA mRNA levels in MDA-MB-231 and MDA-MB-468 were affected by miR-34c (Figure 5B). This suggests that PKCα downregulation is not a mediator of the effects seen by miR-34c in breast cancer cells.

Figure 5.

Figure 5

Open in a new tab

Evaluation of miR-34c targets. Following transfection of MDA-MB-231, MDA-MB-468 and BT-549 (breast cancer cells with miR-34c mimic or negative control for 96 h, cells were analyzed for expression of PRKCA (B), CCND1 (C), CDK4 (D), CDK6 (E) or CDC23 (G) mRNA with real-time quantitative PCR or for protein expression with Western blot (A and F). Data represent mean ± SEM from 2–3 independent experiments and the blots shown are representative of three independent experiments. Asterisks indicate statistically significant differences (* p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t-test) compared to control cells.

To obtain some insight into putative mediators of the miR-34c effect, we next analyzed mRNA and protein levels of the cell cycle regulators cyclin D1, CDK4 and CDK6, which have been identified as targets of miR-34c and its relatives [17, 18, 32]. In line with this, we found that miR-34c overexpression resulted in decreased protein levels of cyclin D1, CDK4 and CDK6 in all cell lines (Figure 5A). A significant decrease in their mRNA levels was also detected (Figure 5C-E).

Cyclin D1, CDK4, and CDK6 are mainly considered to be important in the G1/S transition but the main effect observed following miR-34c treatment was actually an arrest in G2/M. We thus analyzed the protein and mRNA levels of CDC23 which is an important regulator of mitotic progression. CDC23 mRNA has been shown to be pulled-down as well as downregulated by miR-34a in colorectal cancer cells [33] and downregulated by miR-34c in prostate cancer cells [21]. In addition, CDC23 is predicted to contain a putative miR-34c binding site in the 3’UTR by five target prediction tools (MiRanda [23], DIANAmT [24], miRWALK [25], PICTAR5 [26] and Targetscan [27], indicating that CDC23 might be a direct target of miR-34c. A decrease both in protein and mRNA levels of CDC23 was indeed observed in all cell lines following miR-34c expression (Figure 5F-G) suggesting that suppression of CDC23 may mediate some miR-34c effects, either as a direct target of miR-34c or via an indirect mechanism.

To analyse whether suppression of CDC23 levels is sufficient to elicit some miR-34c effects, MDA-MB-231 cells were treated with siRNA targeting CDC23 mRNA (Figure 6). This resulted in fewer cells in the G1 and increases in the G2/M phase. However, no effect on cells in the sub-G1 phase could be seen.

Figure 6.

Figure 6

Open in a new tab

Effects of CDC23 down regulation on cell cycle distribution. MDA-MB-231 cells were treated for 72 h with three separate siRNAs targeting CDC23. Thereafter the cell cycle distribution was analyzed with flow cytometry (A) and CDC23 protein levels were analyzed with Western blot (B). The data in A are mean ± SEM from three separate experiments. Asterisks indicate statistically significant differences (* p < 0.05, *** p < 0.001, paired t-test) compared to control cells.

Discussion

In cancers, dysregulation of miRNA is a common feature that can affect downstream targets and further influence tumorigenic events such as proliferation, metastasis and apoptosis [34]. Family members of miR-34 have been reported to be downregulated in several different cancers, including prostate [10], neuroblastoma [13], colon [11], lung [12] and breast [14, 15]. In addition, epigenetic silencing through CpG methylation [35, 36] and homozygous deletions affecting the miR-34a and miR-34b/c loci (1p36 and 11q23, respectively) has been identified in neuroblastoma and other tumors [5, 7, 37–39].

Our analyses of TCGA data indicate that low levels of miR-34b and/or miR-34c may predict a worse outcome of breast cancer. However, the data are not in line with previous reports indicating that miR-34a and miR-34b are downregulated in breast cancer [40–42]. It was only for miR-34c in basal-like breast cancers that lower expression levels could be seen. This indicates that miR-34c may be the most relevant miR-34 family member to overexpress in basal-like breast cancer cells.

In this study, we have identified an anti-proliferative and pro-apoptotic effect by miR-34c in basal-like breast cancer cells, in concordance with reports from studies in other cancers [16, 21]. Previous studies have pointed out a role for miR-34a [13, 18, 35, 43–45], and in some cases for miR-34c [18, 31], in suppression of the cell cycle, mainly by induction of G1 cell cycle arrest. Our data rather indicate that miR-34c induced a G2/M arrest in breast cancer cells. This is more in line with the miR-34a-promoted mitotic catastrophe and G2/M arrest in irradiated glioblastoma cells [46]. One member of the anaphase-promoting complex (APC), CDC23, has been reported to be a target of miR-34a [33] and show a decreased mRNA expression in response to miR-34c in prostate cancer cells [21]. In our analysis we detect a significant decrease of CDC23 both at mRNA and protein levels in response to miR-34c expression. CDC23 may be a mediator of miR-34c effects, but more specific experiments are needed to settle CDC23 as a direct miR-34c target. The decrease in G1 and increase in G2/M could be replicated by down regulation of CDC23 supporting the hypothesis that downregulation of CDC23 may mediate some of the observed miR-34c effects. However, there was no effect on cells in the sub-G1 phase suggesting that miR-34c-induced cell death may be mediated by other mechanisms.

PKCα protein levels were not influenced by miR-34c and a downregulation of PKCα is therefore conceivably not involved in the observed effects. However, the PRKCA mRNA levels were affected, albeit in different directions depending on cell line. The diverging effects on PRKCA mRNA levels suggest that it is less likely a direct target of miR-34c.

We also observed that miR-34c induces death in breast cancer cells. This could be a consequence of a G2/M arrest or involve other mechanisms, such as suppression of the pro-survival factors BCL2 [13, 32] or SIRT1 [47]. The fact that siCDC23 induces a G2/M arrest, but no increasing in sub-G1 phase, indicates that the effects may be separate. Induction of cell death actually seems to be a more general miR-34 effect since they have been shown to lead to increased cell death in several cell types [5, 10, 48]. Along with the growth-suppressing and cell death-inducing effects shown in this study, miR-34c has been shown to reduce the migratory and self-renewing capacity of breast tumor-initiating cells [49] and to inhibit metastatic invasion in vivo [15]. Our study further indicates that miR-34c has tumor-suppressive effects in breast cancer and, together with other reports, this implies miR-34c to be a potential mediator for novel miRNA replacement therapies [50].

Conclusions

In conclusion, we have detected a suppressive role for miR-34c in breast cancer cell growth and a G2/M cell cycle arrest in response to miR-34c induction. We also identified CDC23 as a miR-34c-regulated target that could be responsible for the miR-34c-induced cell cycle arrest.

Electronic supplementary material

12885_2014_4733_MOESM1_ESM.pdf (25.2KB, pdf)

Additional file 1: Expression levels of miR-34b and miR-34c in breast cancer cell lines. MDA-MB-231, MDA-MB-468 and T47D cells were analyzed for basal expression levels of miR-34b (A) and miR-34c (B). The data are mean ± SEM from three separate experiments. (PDF 25 KB)

12885_2014_4733_MOESM2_ESM.pdf (93.3KB, pdf)

Additional file 2: Effect of miR-34c on cell cycle distribution. Representative cell cycle profiles of breast cancer cell lines transfected with miR-34c mimic or negative control. Quantifications are given in Figure 3. (PDF 93 KB)

Acknowledgements

This work was supported by grants from the Swedish Research Council, the Swedish Cancer Society, the Gunnar Nilsson, Ollie and Elof Ericsson, and Kock foundations, and Malmö University Hospital research funds. The results are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.

Abbreviations

miR

microRNA

TCGA

The Cancer Genome Atlas

3’UTR

3’untranslated region

CCND1

Cyclin D1

CDK4

Cyclin-dependent kinase 4

CDK6

Cyclin-dependent kinase 6

CDC23

Cell division cycle 23

PRKCA

Protein kinase Cα.

Footnotes

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CA and SW contributed to the experimental design, performed the experiments and assembled the drafts of the manuscript. YC participated in interpretative discussions and helped draft the manuscript. CL conceived the study, participated in the design of the experimental work, performed the statistical analyses and helped draft the manuscript. All authors read and approved the final manuscript.

Contributor Information

Chandrani Achari, Email: Chandrani.Achari@med.lu.se.

Sofia Winslow, Email: Sofia.Winslow@med.lu.se.

Yvonne Ceder, Email: Yvonne.Ceder@med.lu.se.

Christer Larsson, Email: Christer.Larsson@med.lu.se.

References

  • 1.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi: 10.1016/j.cell.2009.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466:835–840. doi: 10.1038/nature09267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290–1297. doi: 10.1093/nar/gki200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–450. doi: 10.1016/j.devcel.2006.09.009. [DOI] [PubMed] [Google Scholar]
  • 5.Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017–5022. doi: 10.1038/sj.onc.1210293. [DOI] [PubMed] [Google Scholar]
  • 6.Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551–2556. doi: 10.1158/0008-5472.CAN-07-2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ellsworth RE, Vertrees A, Love B, Hooke JA, Ellsworth DL, Shriver CD. Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Ann Surg Oncol. 2008;15:2519–2525. doi: 10.1245/s10434-008-0051-7. [DOI] [PubMed] [Google Scholar]
  • 8.Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, Deng G. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer. 1997;72:283–288. doi: 10.1002/(SICI)1097-0215(19970717)72:2&#x0003c;283::AID-IJC14&#x0003e;3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 9.Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res. 1995;55:3988–3991. [PubMed] [Google Scholar]
  • 10.Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D, Lilja H, Ceder Y. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer. 2010;127:2768–2776. doi: 10.1002/ijc.25269. [DOI] [PubMed] [Google Scholar]
  • 11.Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58. doi: 10.1186/1756-8722-5-58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM. MiR-34a/c-Dependent PDGFR-alpha/beta Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One. 2013;8:e67581. doi: 10.1371/journal.pone.0067581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008;6:735–742. doi: 10.1158/1541-7786.MCR-07-2102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Javeri A, Ghaffarpour M, Taha MF, Houshmand M. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol. 2013;30:413. doi: 10.1007/s12032-012-0413-7. [DOI] [PubMed] [Google Scholar]
  • 15.Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X, Liu Z. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013;32:4294–4303. doi: 10.1038/onc.2012.432. [DOI] [PubMed] [Google Scholar]
  • 16.Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8438. doi: 10.1158/0008-5472.CAN-07-1585. [DOI] [PubMed] [Google Scholar]
  • 17.Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–1568. doi: 10.1016/j.febslet.2008.03.057. [DOI] [PubMed] [Google Scholar]
  • 18.He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130–1134. doi: 10.1038/nature05939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68:4123–4132. doi: 10.1158/0008-5472.CAN-08-0325. [DOI] [PubMed] [Google Scholar]
  • 20.Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105:13556–13561. doi: 10.1073/pnas.0803055105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hagman Z, Haflidadottir BS, Ansari M, Persson M, Bjartell A, Edsjo A, Ceder Y. The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer. 2013;109:1271–1278. doi: 10.1038/bjc.2013.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM, Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008;68:10128–10136. doi: 10.1158/0008-5472.CAN-08-2148. [DOI] [PubMed] [Google Scholar]
  • 23.Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol. 2003;5:R1. doi: 10.1186/gb-2003-5-1-r1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K, Vergoulis T, Koziris N, Sellis T, Tsanakas P, Hatzigeorgiou AG. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 2009;37:W273–W276. doi: 10.1093/nar/gkp292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44:839–847. doi: 10.1016/j.jbi.2011.05.002. [DOI] [PubMed] [Google Scholar]
  • 26.Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500. doi: 10.1038/ng1536. [DOI] [PubMed] [Google Scholar]
  • 27.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
  • 28.Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer. 2010;9:76. doi: 10.1186/1476-4598-9-76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest. 1995;95:1906–1915. doi: 10.1172/JCI117872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein Kinase C alpha Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells. Cancer Cell. 2013;24:347–364. doi: 10.1016/j.ccr.2013.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC, Elia A, Kress TR, Dickens M, Clemens MJ, Heery DM, Gaestel M, Willis AE, Bushell M. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A. 2010;107:5375–5380. doi: 10.1073/pnas.0910015107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–1307. doi: 10.1016/j.cub.2007.06.068. [DOI] [PubMed] [Google Scholar]
  • 33.Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, Deutsch A, Hofmann O, Ventura A, Hide W, Lieberman J. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011;7:e1002363. doi: 10.1371/journal.pgen.1002363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Di Leva G, Garofalo M, Croce CM. MicroRNAs in Cancer. Annu Rev Pathol. 2013;9:287–314. doi: 10.1146/annurev-pathol-012513-104715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–2600. doi: 10.4161/cc.7.16.6533. [DOI] [PubMed] [Google Scholar]
  • 36.Vrba L, Munoz-Rodriguez JL, Stampfer MR, Futscher BW. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One. 2013;8:e54398. doi: 10.1371/journal.pone.0054398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression–a matter of dosage? Cancer Res. 2012;72:6079–6088. doi: 10.1158/0008-5472.CAN-12-2230. [DOI] [PubMed] [Google Scholar]
  • 38.Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994;54:4586–4589. [PubMed] [Google Scholar]
  • 39.Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleno N, Martinez G, Posso H, Evans GA, Murty VV. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res. 2000;60:6677–6682. [PubMed] [Google Scholar]
  • 40.Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13:109–117. doi: 10.1007/s10238-012-0186-5. [DOI] [PubMed] [Google Scholar]
  • 41.Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, Yong Z, Jundong Z, Qianyong Z, Mantian M. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res. 2012;14:R80. doi: 10.1186/bcr3194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC, Chen HW. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res. 2011;13:R116. doi: 10.1186/bcr3059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593. doi: 10.4161/cc.6.13.4436. [DOI] [PubMed] [Google Scholar]
  • 44.Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569–7576. doi: 10.1158/0008-5472.CAN-09-0529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene. 2013;32:1155–1163. doi: 10.1038/onc.2012.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kofman AV, Kim J, Park SY, Dupart E, Letson C, Bao Y, Ding K, Chen Q, Schiff D, Larner J, Abounader R. microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle. 2013;12:3500–3511. doi: 10.4161/cc.26459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105:13421–13426. doi: 10.1073/pnas.0801613105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Liang X, Zhou D, Wei C, Luo H, Liu J, Fu R, Cui S. MicroRNA-34c enhances murine male germ cell apoptosis through targeting ATF1. PLoS One. 2012;7:e33861. doi: 10.1371/journal.pone.0033861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X, Liu Y, He Y, Park EY, Zhang H, Lv X, Ma K, Su F, Park JH, Song E. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem. 2012;287:465–473. doi: 10.1074/jbc.M111.280768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120. doi: 10.3389/fgene.2012.00120. [DOI] [PMC free article] [PubMed] [Google Scholar]

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/538/prepub

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12885_2014_4733_MOESM1_ESM.pdf (25.2KB, pdf)

Additional file 1: Expression levels of miR-34b and miR-34c in breast cancer cell lines. MDA-MB-231, MDA-MB-468 and T47D cells were analyzed for basal expression levels of miR-34b (A) and miR-34c (B). The data are mean ± SEM from three separate experiments. (PDF 25 KB)

12885_2014_4733_MOESM2_ESM.pdf (93.3KB, pdf)

Additional file 2: Effect of miR-34c on cell cycle distribution. Representative cell cycle profiles of breast cancer cell lines transfected with miR-34c mimic or negative control. Quantifications are given in Figure 3. (PDF 93 KB)

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES